thiamet-g has been researched along with Tauopathies* in 3 studies
3 other study(ies) available for thiamet-g and Tauopathies
Article | Year |
---|---|
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer's disease and progressive supranuclear palsy. Beginning with carbohydrate-based lead molecules, we pursued an optimization strategy of reducing polar surface area to align the desired drug-like properties of potency, selectivity, high central nervous system (CNS) exposure, metabolic stability, favorable pharmacokinetics, and robust in vivo pharmacodynamic response. Herein, we describe the medicinal chemistry and pharmacological studies that led to the identification of (3a Topics: Administration, Oral; Animals; beta-N-Acetylhexosaminidases; Biological Availability; Brain; Dogs; Drug Discovery; Enzyme Inhibitors; Humans; Macaca mulatta; Male; PC12 Cells; Rats; Rats, Wistar; Structure-Activity Relationship; Tauopathies | 2019 |
Sugar Kick Prevents Memory Impairment.
Pathological hyperphosphorylation of tau and subsequent aggregation to form neurofibrillary tangles (NFTs) is closely related to progression of neurodegenerative diseases such as Alzheimer's disease (AD) and progressive supranuclear palsy. A recent study showed that MK-8719 ( Topics: Alzheimer Disease; beta-N-Acetylhexosaminidases; Brain; Humans; Neurofibrillary Tangles; Phosphorylation; Sugars; tau Proteins; Tauopathies | 2019 |
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
Pathological hyperphosphorylation of the microtubule-associated protein tau is characteristic of Alzheimer's disease (AD) and the associated tauopathies. The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and reductions in O-GlcNAc levels on tau in AD brain offers motivation for the generation of potent and selective inhibitors that can effectively enhance O-GlcNAc in vertebrate brain. We describe the rational design and synthesis of such an inhibitor (thiamet-G, K(i) = 21 nM; 1) of human O-GlcNAcase. Thiamet-G decreased phosphorylation of tau in PC-12 cells at pathologically relevant sites including Thr231 and Ser396. Thiamet-G also efficiently reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus, which reveals the rapid and dynamic relationship between O-GlcNAc and phosphorylation of tau in vivo. We anticipate that thiamet-G will find wide use in probing the functional role of O-GlcNAc in vertebrate brain, and it may also offer a route to blocking pathological hyperphosphorylation of tau in AD. Topics: Animals; beta-N-Acetylhexosaminidases; Brain Chemistry; Cerebral Cortex; Enzyme Inhibitors; Hippocampus; Humans; Phosphorylation; Rats; tau Proteins; Tauopathies | 2008 |